1Jay V. The legacy of Laennec [ J ]. Arch Pathol Lab Med, 2000,124 : 1420 - 1421.
2Bloch H. The inventor of the stethoscope: Rene Laennec [ J]. J Fam Pract, 1993,37 : 191.
3Guo J, Kong Y, Si L, et al. Analysis of KIT, BRAF and NRAS mutations in Chinese distinctive subtypes of melanoma [C]. Meeting Abstracts in perspectives in melanoma XIII,2009.
4Flaherty K,Puzanov I, Sosman J, et al. Phase Ⅰ study of PLX4032 : Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer [J]. J Clin Oncol, 2009,27(15S) :9000.
5Carvajal RD,Chapman PB,Wolchok JD,et al. A phase Ⅱ study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT [J]. J Clin Oncol,2009(15S),27:9001.
6Si L,Guo J,George X,et al. A phase Ⅱ study of Imatinib for selected Chinese patients of advanced melanoma with KIT aberrations[C]. Meeting Abstracts in Perspectives in Melanoma XIII,2009.
7Hamid O, Chasalow SD, Tsuchihashi Z, et al. Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab [ J ]. J Clin Oncol, 2009,27(15S) :9008.
8O'Day S,Weber J, Lebbe C, et al. Effect of ipilimumab treatment on 18-month survival: Update of patients ( pts ) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase Ⅱ clinical trials [ J ]. J Clin Oncol,2009,27(15S) :9033.
9Kluger HM, Dudek A, McCann C, et al. A phase Ⅱ trial of dasatinib in advanced melanoma [J]. J CIin Oncol, 2009,27 (15S) :9010.
10Woodman SE, Trent JC, Stemke-Hale K, et al. Selective activity of dasatinib for the most common KIT mutation in melanoma (L576P) [J]. J Clin Oncol, 2009, 27 (15S) :9019.
